Search Results - "Scholten, Jeffrey A."
-
1
Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1
Published in Biochemical journal (15-05-2012)“…SphK (sphingosine kinase) is the major source of the bioactive lipid and GPCR (G-protein-coupled receptor) agonist S1P (sphingosine 1-phosphate). S1P promotes…”
Get more information
Journal Article -
2
Discovery of a Potent and Selective Sphingosine Kinase 1 Inhibitor through the Molecular Combination of Chemotype-Distinct Screening Hits
Published in Journal of medicinal chemistry (23-03-2017)“…Sphingosine kinase (SphK) is the major source of the lipid mediator and G protein-coupled receptor agonist sphingosine-1-phosphate (S1P). S1P promotes cell…”
Get full text
Journal Article -
3
Discovery of N‑(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)‑5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)‑2H‑tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis
Published in Journal of medicinal chemistry (14-01-2016)“…Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular…”
Get full text
Journal Article -
4
Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: Use of a conformation-based hypothesis to facilitate compound design
Published in Bioorganic & medicinal chemistry letters (15-02-2013)“…Microsomal prostaglandin E2 synthase-1 (mPGES-1) is a novel therapeutic target for the treatment of inflammation and pain. In the preceding letter, we detailed…”
Get full text
Journal Article -
5
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis
Published in Bioorganic & medicinal chemistry letters (15-01-2010)“…Potent, highly selective and orally-bioavailable MMP-13 inhibitors have been identified based upon a (pyridin-4-yl)-2H-tetrazole scaffold. Co-crystal structure…”
Get full text
Journal Article -
6
Discovery of N -(4-Fluoro-3-methoxybenzyl)-6-(2-(((2 S ,5 R )-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2 H -tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis
Published in Journal of medicinal chemistry (14-01-2016)Get full text
Journal Article -
7
Discovery of (pyridin-4-yl)-2 H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis
Published in Bioorganic & medicinal chemistry letters (2010)“…Potent, highly selective and orally-bioavailable MMP-13 inhibitors have been identified which inhibit production of type II collagen neoepitope (TIINE), a…”
Get full text
Journal Article -
8
3-Methyl-4H-[1,2,4]-oxadiazol-5-one: a versatile synthon for protecting monosubstituted acetamidines
Published in Tetrahedron (22-11-2004)Get full text
Journal Article -
9
3-Methyl-4 H-[1,2,4]-oxadiazol-5-one: a versatile synthon for protecting monosubstituted acetamidines
Published in Tetrahedron (2004)“…The utilization of 3-methyl-4 H-[1,2,4]-oxadiazol-5-one as a versatile protected acetamidine is demonstrated through employment in a variety of synthetic…”
Get full text
Journal Article